8-K ·Filed Jun 8, 2026

NOTV

Inotiv, Inc.
BEARISH
Impact 9/10
Horizonimmediate Processed3mo ago SEC0001628280-26-041667
8-K context-dependent: Items 8.01
Actionable Insight ▼ Bearish

Common equity is expected to be worthless. Traders should exit any long positions immediately. Monitor the Chapter 11 process for potential recovery for creditors, but equity holders are unlikely to receive any value.

DirectionBearish
Confidencehigh
Horizonimmediate
Latest settled — T+1d
NOTV ▼ -15.89% at T+1d
SHORT call ✓ call won +15.89% · α vs SPY +14.32% · entry $0.0950 → $0.0799
Next anchor: T+5d due 4mo ago
Latest observation: T+17 +195.44% FF3 residual α
Entry anchored
Jun 8, 03:59 PM ET
via exchange tick
T+1d
-15.89%
call +15.89% · α +14.32%
$0.0799
settled 4mo ago
T+5d
—
call — · α —
—
due 4mo ago
T+20d
—
call — · α —
—
due 3mo ago
T+60d
—
call — · α —
—
due 4w ago

Price Chart

Loading chart...

Executive Summary

Inotiv filed for Chapter 11 bankruptcy on June 3, 2026, and entered into a $65.5M DIP credit facility on June 5, 2026. Nasdaq notified the company of delisting effective June 11, 2026, and the company expects existing equity interests to be cancelled with no distribution. Common equity is essentially worthless.

Key Facts

  • Filed Chapter 11 bankruptcy on June 3, 2026
  • Entered $65.5M DIP credit facility ($25M new money + $40.5M roll-up)
  • Nasdaq notified delisting of common shares effective June 11, 2026
  • Company expects existing equity interests to be cancelled with no distribution

Financial Impact

Equity holders expected to receive no distribution; $65.5M DIP facility secured by superpriority liens; potential total loss for common shareholders.

equity value

Risk Factors

  • Equity holders expected to receive zero recovery
  • Delisting will eliminate liquidity in common shares
  • Plan confirmation risks could delay or alter outcomes

Market Snapshot

Exchange
Nasdaq
Sector
Services-Commercial Physical & Biological Research
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-041667
Document: notv-20260604.htm0001628280-26-041667
Document: 0001628280-26-041667-index-headers.html0001628280-26-041667
Document: 0001628280-26-041667-index.html0001628280-26-041667
Document: 0001628280-26-041667.txt0001628280-26-041667
4 reports for NOTV
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+20▲ +96.13%Jun 1, 2026
Filters
Rows
Reports for NOTV — sortable, filterable
TypeNow
Jun 8, 2026
16w ago
8-K
BEARISH ★ 9/10
$0.0950 $0.0799▲ +15.89%▲ +14.32%—
Jun 3, 2026
17w ago
8-K
BEARISH ★ 8/10
$0.1200 $0.0900▲ +25.00%▲ +25.40%—
Jun 1, 2026
17w ago
8-K
BEARISH ★ 7/10
$0.3100 $0.2600▲ +16.13%▲ +16.27%—
Mar 24, 2026
27w ago
8-K
BEARISH ★ 7/10
$0.3200 $0.3000▲ +6.25%▲ +6.82%—
Showing 4 of 4

US Market Status

Market Closed — Opens Mon (38h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access